Pulse Biosciences Inc.

09/13/2021 | Press release | Archived content

Correspondence (Form CORRESP)

CORRESP

PULSE BIOSCIENCES, INC.

3957 Point Eden Way

Hayward, California 94545



September13, 2021

Via EDGAR



U.S. Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, NE

Washington, D.C. 20549-3561

Attention:Ms. Christine Westbrook



Re:

Pulse Biosciences, Inc.



Registration Statement on Form S-3



Filed September 3, 2021



File No. 333-259330





Acceleration Request



Requested Date: September 15, 2021



Requested Time: 4:00 p.m. Eastern Time



Ladies and Gentlemen:



Pursuant to Rule 461 under the Securities Act of 1933, as amended, Pulse Biosciences, Inc. (the "Company") hereby requests that the above-referenced Registration Statement on Form S-3 (File No. 333-259330) (the "Registration Statement"), be declared effective at the "Requested Date" and "Requested Time" set forth above or as soon thereafter as practicable, or at such later time as the Company may request by telephone to the staff of the Securities and Exchange Commission.



The Company hereby authorizes Ken Stratton, the Company's General Counsel, to make such request on the Company's behalf.



The Company requests that it be notified of the effectiveness of the Registration Statement by contacting Ken Stratton at (510) 905-1106 or [email protected]







Sincerely,

PULSE BIOSCIENCES, INC.



By:

/s/ Sandra A. Gardiner

Sandra A. Gardiner

Chief Financial Officer, Executive Vice President of Finance and Administration, Secretary and Treasurer





cc:

Darrin R. Uecker, Pulse Biosciences, Inc.



Kenneth B. Stratton, Esq., Pulse Biosciences, Inc.



Andrew D. Hoffman, Esq., Wilson Sonsini Goodrich & Rosati, P.C.